Matches in Wikidata for { <http://www.wikidata.org/entity/Q65364452> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q65364452 description "clinical trial" @default.
- Q65364452 description "ensayu clínicu" @default.
- Q65364452 description "klinisch onderzoek" @default.
- Q65364452 description "клінічне випробування" @default.
- Q65364452 name "Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy" @default.
- Q65364452 name "Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy" @default.
- Q65364452 type Item @default.
- Q65364452 label "Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy" @default.
- Q65364452 label "Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy" @default.
- Q65364452 prefLabel "Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy" @default.
- Q65364452 prefLabel "Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy" @default.
- Q65364452 P1050 Q65364452-16D31CFB-535A-41B6-A63D-FB5495A885F8 @default.
- Q65364452 P1050 Q65364452-5370ED8F-A4FA-4F34-BC0E-C39B552351A1 @default.
- Q65364452 P1132 Q65364452-978BE2B5-3CBD-4FA9-8C22-BA631C79F86E @default.
- Q65364452 P1476 Q65364452-22AC50E9-776F-40EF-8BBA-021245861D89 @default.
- Q65364452 P17 Q65364452-A21B8B30-E8D9-4C60-A771-28A7DAF29089 @default.
- Q65364452 P2899 Q65364452-59BBFA37-7805-461E-9918-2127EB3CDC4F @default.
- Q65364452 P3098 Q65364452-FB83516A-1FBC-4FB7-8B13-DBAA46996581 @default.
- Q65364452 P31 Q65364452-F274BD22-85E9-42F7-888D-369E7576AD68 @default.
- Q65364452 P4844 Q65364452-C2878D16-DC69-4C07-8E57-072A757E5621 @default.
- Q65364452 P580 Q65364452-BEC4AC34-3DF1-40E7-8742-7DB908AA01FA @default.
- Q65364452 P582 Q65364452-3F22AB5D-F12F-47C3-8C8E-408CDD65A165 @default.
- Q65364452 P6099 Q65364452-81BE28ED-FFCF-4F8D-87C8-48C4F990D3B8 @default.
- Q65364452 P6153 Q65364452-C2B64BFA-5EF5-4B54-B1FD-016864474CEA @default.
- Q65364452 P8363 Q65364452-5E564331-048D-4FE6-8411-E696EDFBBE87 @default.
- Q65364452 P1050 Q179630 @default.
- Q65364452 P1050 Q29496 @default.
- Q65364452 P1132 "+74" @default.
- Q65364452 P1476 "A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy" @default.
- Q65364452 P17 Q30 @default.
- Q65364452 P2899 "+18" @default.
- Q65364452 P3098 "NCT01869114" @default.
- Q65364452 P31 Q30612 @default.
- Q65364452 P4844 Q32089 @default.
- Q65364452 P580 "2013-07-08T00:00:00Z" @default.
- Q65364452 P582 "2019-07-08T00:00:00Z" @default.
- Q65364452 P6099 Q42824440 @default.
- Q65364452 P6153 Q2471216 @default.
- Q65364452 P8363 Q78089383 @default.